Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian stock markets back in green
Wed, 8 May 01:30 pm

Indian stock markets are trading in the positive territory during the post noon trading session. The most noticeable upward movement has been noticed in the FMCG and IT sectors, while capital goods and power stocks are facing maximum selling pressure.

BSE-Sensex is up by 87 points and NSE-Nifty is trading up by 19 points. While BSE Mid Cap is trading up by 0.3%, BSE Small Cap index is trading up by 0.3%. The rupee is trading at 54.05 to the US dollar.

Barring Corporation Bank, all public sector banking stocks are trading in the red with UCO Bank and Allahabad Bank being the biggest losers. As per a leading financial daily, State Bank of India (SBI) is targeting to achieve a growth of 15-20% in deposits for FY14. The bank had reported a 14.9% deposit growth in FY13 as compared to 13% growth posted by the banking industry. The banking major has partly attributed the slowdown in deposit mobilization in FY13 to the absence of a level playing field with the mutual funds industry. The corporate sector having excess funds invest in liquid funds that have short maturities. But with bank regulations not allowing investible products with maturity period of less than seven days, the banks have not been able to tap this source of funds. SBI's projection for FY14 is also higher than Reserve Bank of India's forecast of 14% deposit growth for the banking industry during the fiscal. SBI stock is currently down 0.6%.

Indian pharma stocks desc are trading mixed. While Cadila Healthcare and Lupin Ltd are leading among the gainers, Ranbaxy Laboratories and Dishman Pharma are trading weak. Glenmark Pharma declared its results for the fourth quarter and year ended March 2013. The topline of the company grew by 25% YoY for the quarter. The growth was led by both its speciality and generics segments. The domestic segment witnessed growth of 32% YoY for the said period. This was due to increasing market share in therapies viz., dermatology, respiratory, cardiac and anti infective segments. The US geography too witnessed robust growth of 25% YoY during the quarter. However, operating margins witnessed decline of 1.8% due to mark to market (MTM) forex loss of Rs 150 m and increase in other expenditure. The bottom line grew by 11% YoY for the said period. Glenmark is trading up by 0.8%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian stock markets back in green". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.